Literature DB >> 25297391

Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis.

Lars Kamper1, Alexander Sascha Brandt, Hendrik Ekamp, Nadine Abanador-Kamper, Werner Piroth, Stephan Roth, Patrick Haage.   

Abstract

PURPOSE: We aimed to evaluate diffusion-weighted imaging (DWI) findings in patients with treated and untreated retroperitoneal fibrosis (RPF).
METHODS: We analyzed magnetic resonance imaging examinations of 44 RPF patients (36 male, 8 female), of which 15 were untreated and 29 were under therapy. Qualitative DWI and T1 postcontrast signal intensities and the largest perivascular extent of RPF were compared between treated and untreated groups and correlated to erythrocyte sedimentation rate and C-reactive protein values. Quantitative DWI signal intensities and apparent-diffusion-coefficients were calculated in regions-of-interest, together with a relative index between signal intensities of RPF and psoas muscle in 15 untreated patients and 14 patients under treatment with remaining perivascular fibrosis of more than 5 mm.
RESULTS: The extent of RPF in untreated patients was significantly larger compared with the extent of RPF in treated patients (P <0.0001). DWI signal intensities were significantly higher in untreated patients than in patients under therapy (mean, 27 s/mm2 vs. 20 s/mm2; P = 0.009). The calculated DWI-index was significantly higher in untreated patients than in patients under therapy (P = 0.003).
CONCLUSION: Our data show significant differences in the DWI findings (b800 signal intensities and relative DWI-index) of patients with treated and untreated RPF. DWI is a promising technique in the assessment of disease activity and the selection of patients suitable for medical therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25297391      PMCID: PMC4463287          DOI: 10.5152/dir.2014.14027

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  23 in total

1.  Is quantitative diffusion-weighted MRI a reliable method in the assessment of the inflammatory activity in ulcerative colitis?

Authors:  Ozgür Kılıçkesmez; Aliye Soylu; Nurgül Yaşar; Tuna Demirbaş; Can Dolapçıoğlu; Sule Poturoğlu; Isa Sevindir; Tan Cimilli
Journal:  Diagn Interv Radiol       Date:  2010-08-09       Impact factor: 2.630

Review 2.  Imaging and intervention of retroperitoneal fibrosis.

Authors:  T Geoghegan; A T Byrne; W Benfayed; G McAuley; W C Torreggiani
Journal:  Australas Radiol       Date:  2007-02

Review 3.  Diffusion-weighted MRI for detecting and monitoring cancer: a review of current applications in body imaging.

Authors:  Barış Türkbey; Ömer Aras; Nevzat Karabulut; Ahmet Tuncay Turgut; Erhan Akpinar; Sedat Alibek; Yuxi Pang; Şükrü Mehmet Ertürk; Riham H El Khouli; David A Bluemke; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2011-09-19       Impact factor: 2.630

4.  Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry.

Authors:  A S Brandt; L Kamper; S Kukuk; P Haage; S Roth
Journal:  J Urol       Date:  2010-12-18       Impact factor: 7.450

Review 5.  Retroperitoneal fibrosis.

Authors:  Augusto Vaglio; Carlo Salvarani; Carlo Buzio
Journal:  Lancet       Date:  2006-01-21       Impact factor: 79.321

Review 6.  Ormond's disease or secondary retroperitoneal fibrosis? An overview of retroperitoneal fibrosis.

Authors:  M Heckmann; M Uder; M A Kuefner; M C Heinrich
Journal:  Rofo       Date:  2009-03-16

7.  Evaluation of diffusion-weighted MR imaging for detection of bowel inflammation in patients with Crohn's disease.

Authors:  Aytekin Oto; Fang Zhu; Kirti Kulkarni; Gregory S Karczmar; Jerrold R Turner; David Rubin
Journal:  Acad Radiol       Date:  2009-03-17       Impact factor: 3.173

8.  Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis.

Authors:  Paul R Burn; Sadmeet Singh; Syed Barbar; Gregory Boustead; Chris M King
Journal:  Can Assoc Radiol J       Date:  2002-06       Impact factor: 2.248

9.  Usefulness of the calculated apparent diffusion coefficient value in the differential diagnosis of retroperitoneal masses.

Authors:  Tomohiro Nakayama; Kengo Yoshimitsu; Hiroyuki Irie; Hitoshi Aibe; Tsuyoshi Tajima; Kenji Shinozaki; Akihiro Nishie; Yoshiki Asayama; Daisuke Kakihara; Shuji Matsuura; Hiroshi Honda
Journal:  J Magn Reson Imaging       Date:  2004-10       Impact factor: 4.813

10.  Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis?

Authors:  Marina N Magrey; M Elaine Husni; Irving Kushner; Leonard H Calabrese
Journal:  Arthritis Rheum       Date:  2009-05-15
View more
  5 in total

1.  Diffusion-weighted MRI and PET-CT in the follow up of chronic periaortitis.

Authors:  L Kamper; N M Dreger; A S Brandt; T Pöppel; N Abanador-Kamper; S Roth; P Haage
Journal:  Int J Cardiovasc Imaging       Date:  2018-06-15       Impact factor: 2.357

2.  (18)F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease.

Authors:  Verena Ruhlmann; Thorsten Dirk Poeppel; Alexander Sascha Brandt; Johannes Grüneisen; Marcus Ruhlmann; Jens Matthias Theysohn; Michael Forsting; Andreas Bockisch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-11       Impact factor: 9.236

3.  Diffusion-weighted MRI in the follow-up of chronic periaortitis.

Authors:  L Kamper; P Haage; A S Brandt; W Piroth; N Abanador-Kamper; S Roth; H Ekamp
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

Review 4.  [New (and old) aspects of retroperitoneal fibrosis].

Authors:  A S Brandt; N M Dreger; E Müller; S Kukuk; S Roth
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

5.  A Clinical Approach to Diffusion-Weighted Magnetic Resonance Imaging in Evaluating Chest Wall Invasion of Breast Tumors.

Authors:  Naziya Samreen; Christine Lee; Asha Bhatt; Jodi Carter; Tina Hieken; Kalie Adler; Shannon Zingula; Katrina N Glazebrook
Journal:  J Clin Imaging Sci       Date:  2019-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.